Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
8.71
-0.10 (-1.14%)
Jun 27, 2025, 4:00 PM - Market closed
Bicara Therapeutics Employees
Bicara Therapeutics had 55 employees as of December 31, 2024.
Employees
55
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,678,782
Market Cap
475.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCAX News
- 17 days ago - Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus - Seeking Alpha
- 24 days ago - Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 27 days ago - Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewsWire
- 5 weeks ago - Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity - Seeking Alpha
- 5 weeks ago - Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire